medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2003, Number 2

<< Back Next >>

Ann Hepatol 2003; 2 (2)

A rational use of laboratory tests in the diagnosis and management of hepatitis C virus infection

Dal Molin G, Tiribelli C, Campello C

Language: English
References: 69
Page: 76-83
PDF size: 73.23 Kb.


Text Extraction

The prevalence of HCV infection is very diversified according to geographical areas and ranges from 1% in the Northern regions of the world to more than 20% as we move South. Due to the presence of HCV-associated liver diseases and the development of effective treatments, the diagnosis of HCV infection is a growing medical need. Several tests are available, from simple screening to identify the presence of anti-HCV antibodies to the more sophisticated quantification of viral load and genotyping. However, these tests are to be used in a logical, consequential and cost-effective manner. This review article will report on the protocol in use in the North-Eastern part of Italy for the screening and diagnosis of HCV infection. The protocol is based on a consensus among several experts and may be the basis for a more rational approach in this rapidly growing field.


REFERENCES

  1. Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997; 26: 43S-47S.

  2. Pawlotsky JM, Maisonneuve P, Duval J, Dhumeaux D, Noel L. Significance of NS5 “indeterminate” third-generation anti-hepatitis C virus serology assay. Transfusion 1995; 35: 453-454.

  3. Vrielnik H, Zaaijer HL, Reesnik HW, van der Poel CL, Cuypers HTM, Lelie PN. Sensitivity and specificity of three third –generation anti-hepatitis C virus ELISAs. Vox Sang 1995; 69: 14-17.

  4. Lavanchy D, Steinmann J, Moritz A, Frei PC. Evaluation of a new automated third-generation anti-HCV enzyme immunoassay. J Clin Lab Anal 1996; 10: 269-276.

  5. De Medina M, Hill M, Sullivan HO, Leclerq B, Pennell JP, Jeffers L, Reddy KR, et al. Detection of anti-hepatitis C virus antibodies in patients undergoing dialysis by utilizing a hepatitis C virus 3.0 assay: correlation with hepatitis C virus RNA. J Lab Clin Med 1998; 132: 73-75.

  6. Zylberberg H, Pol S. Reciprocal interaction between human immunodeficiency virus and hepatitis C infection. Clin Infect Dis 1996; 23: 1117-1125.

  7. Quaranta JF, Delaney SR, Alleman S, Cassuto JP, Dellamonica P, Allain JP. Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (Nice SEROCO cohort). J Med Virol 1994; 42: 29-32.

  8. Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercial available antibody tests to identify a significant number of patients with HCV infection. J Infect Dis 1993; 168: 1343-1348.

  9. Donegan E, Wright TL, Roberts J, Ascher NL, Lake JR, Newvald P, Wilber J, et al. Detection of hepatitis C after liver transplantation. Four serologic tests compared. Am J Clin Pathol 1995; 104: 673-679.

  10. Johnson RJ, Gretch DR, Yambe H, Hart J, Bacchi CE, Hartwell P, Couser WG, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-470.

  11. Barrera J, Prancis B, Ercilla G, Nelles M, Achord D, Darner J, Lee S. Improved detection of anti-HCV in post-transfusion hepatitis by a third generation ELISA. Vox Sang 1995; 68: 15-18.

  12. Busch M, Tobler L, Francis B. Re-instatement of donors who test false-positive in second generation hepatitis C virus enzyme immunoassay should await availability of licensed third-generation tests. Transfusion 1994; 34: 130-134.

  13. Courouce AM, Bouchardeau F, Girault A, Le Marrec N. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994; 343: 853-854.

  14. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. Hepatology 2002; 36: S3-S20.

  15. Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, Soussy CJ, et al. Wath strategy should be use for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 1700-1702.

  16. Pawlotsky JM, Bastie A, Pellet C, Remire J, Darthuy F, Wolfe L, Sayada C. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assays. J Clin Microbiol 1996; 34: 80-83.

  17. Houghton M. Hepatitis C viruses. In: Fields BN, Knipe DM, Howley PM, editors. Fields Virology. 3rd. Philadelphia: Lippincott-Raven Publishers, 1996: 1035-1058.

  18. Sayers MH, Gretch DR. Recombinant immunoblot and polymerase chain reaction testing in volunteer whole blood donors screened by mult-antigens assay for hepatitis C virus antibodies. Transfusion 1993; 33: 809-813.

  19. Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40: 1165-1168.

  20. Chau KH, Dawson GJ, Mushahwar IK, Gutierrez RA, Johnsson RG, Lesniewski RR, Mattsson L, et al. IgM antibody response to hepatitis C virus antigens in acute and chronic postransfusion non-A, non-B hepatitis. J Virol Methods 1991; 34: 343-352.

  21. Quiroga JA, Campillo M, Castillo I, Bartolomé J, Porres JC, Carreno V. IgM antibody to hepatitis C virus in acute and chronic hepatitis C. Hepatology 1991; 14: 38-43.

  22. Hellstrom UB, Sylvan SPE, Decker RH, Sonnerborg A. Immunoglobulin M reactivity towards the immunologically active region sp75 of the core protein of hepatitis C virus (HCV) in chronic HCV infection. J Med Virol 1993; 39: 325-332.

  23. Dal Molin G, D’Agaro P, Ansaldi F, Ciana G, Fertz C, Alberico S, Campello C. Mother-to-infant transmission of Hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors. J Med Virol 2002; 67: 137-142.

  24. Zaaijer HL, Cuypers HT, Reesnik HW, Winkel IN, Gerken G, Lelie PN. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993; 341: 722-724.

  25. French Study Group for the Standardization of Hepatitis C Virus PCR. Improvement of hepatitis C virus RNA polymerase chain reaction through a multicenter quality control study. J Virol Methods 1995; 49: 79-88.

  26. Damen M. Cuypers HT, Zaajier HL, Reesnik HW, Schaasberg WP, Gerlich WH, Niesters HG, et al. International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Methods 1996; 58: 175-185.

  27. Halfon P, Khiri H, Gerolami V, Bourlière M, Féryn M, Reyner P, Gauthier A, et al. Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA. J Hepatol 1996; 25: 307-311.

  28. Schiff ER, Medina M, Khan RS. New perspectives in the diagnosis of hepatitis C. Semin Liver Dis 1999; 19 (s 1): 3-15.

  29. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assay. Hepatology 2000; 32: 818-823.

  30. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 654-659.

  31. European Association for the Study of the Liver. EASL International Consensus Conference on Hepatitis C. (Paris, 26-28, February 1999, Consensus Statement). J Hepatol 1999; 30: 956-961.

  32. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J, and the ALGOVIRC Project Group. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31: 211-218.

  33. Urdea MS, Horn T, Fultz TJ, Anderson M, Running JA, Hamren S, Ahle D, et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser 1991; 24: 197-200.

  34. Collins ML, Zayati C, Detmer JJ, Daly B, Kolberg JA, Cha TA, Irvine BD, et al. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem 1995; 226: 120-129.

  35. Saldahna J, Lelie N, Heat A, and the WHO Collaborative Study Group. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang 1999; 76: 149-158.

  36. Saldanha J, Heath A, Lelie N, Pisani G, Nubling M, Yu M, and the Collaborative Study Group. Calibration of HCV working reagents for NAT assays against the HCV international standard. Vox Sang 2000; 78: 217-224.

  37. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36: 565- 573.

  38. Fried MW, Shiffman ML, Reddy K, Smith C, Marinos G, Goncales FL Jr, Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.

  39. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis International Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.

  40. McHutchison JC, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK , Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.

  41. Consensus Conference Treatment of hepatitis C. Agence Nationale d’Accréditation et d’Evaluation en Santé (ANAES). Gastroenterol Clin Biol 2002; 26: B303-B320.

  42. Di Biscelie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36: S121-S127.

  43. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (NY) 1993; 11: 1026-1030.

  44. Enomoto M, Nishiguchi S, Shiomi S, Tanaka M, Fukuda K, Ueda T, Tamori A, et al. Comparison of real-time quantitative polymerase chain reaction with three other assays for quantitation of hepatitis C virus. J Gastroenterol Hepatol 2001; 16: 904-909.

  45. Martell M, Gomez J, Esteban JI, Sauleda S, Quer J, Cabot B, Esteban R, et al. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol 1999; 37: 327-332.

  46. Takeuchi T, Katsume A, Tanaka T, Abe A, Inoue K, Tsukiyama-Kohara K, Kawaguchi R, et al. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 1999; 116: 636-642.

  47. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63.

  48. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine BD, Beall E, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391-2399.

  49. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36: S145-S151.

  50. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999; 31 (Suppl 1): 54-60.

  51. Davidson F, Simmonds P, Ferguson JC, Jarvis LM, Dow BC, Follett EA, Seed CR, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5’ non coding region. J Gen Virol 1995; 76: 1197-1204.

  52. Okamoto H, Kobata S, Tokita H, Inoue T, Woodfield GD, Holland PV, Al-Knawy BA, et al. A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene. J Virol Methods 1996; 57: 31-45.

  53. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-1102.

  54. Ross RS, Viazov SO, Holtzer CD, Beyou A, Monnet A, Mazure C, Roggendorf M. Genotyping of hepatitis C virus isolates using CLIP sequencing. J Clin Microbiol 2000; 38: 3581-3584.

  55. Stuyver L, Wyseur A, Van Amhem W, Hemandez F, Maertens G. Second generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 2259-2266.

  56. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13: 223-235.

  57. Pawlotsky JM, Prescott L, Simmonds P, Pellet C, Laurent-Puig P, Labonne C, Darthuy F, et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol 1997; 35: 1734-1739.

  58. Kobayashi M, Chayama K, Arase Y, Tsubota A, Saitoh S, Suzuki Y, Ikeda K, et al. Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6. J Gastroenterol 1999; 34: 505-509.

  59. Leruez-Ville M, Nguyen QT, Cohen P, Cocco S, Nouyou M, Ferriere F, Deny P. Large-scale analysis of hepatitis C virus serological typing assay: effectiveness and limits. J Med Virol 1998; 55: 18-23.

  60. Sandres K, Dubois M, Pasquier C, Puel J, Izopet J. Determination of HCV genotype using two antibody assay and genome typing. Eur J Clin Microbiol Infect Dis 2001; 20: 666-669.

  61. Prescott LE, Berger A, Pawlotsky JM, Conjeevaram P, Pike I, Simmonds P. Sequence analysis of hepatitis C virus variants producing discrepant results with two different genotyping assays. J Med Virol 1997; 53: 237- 244.

  62. Manns MP, McHutchison JC, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.

  63. Courouce AM, Le Marrec N, Bouchardeau F, Razer A, Maniez M, Laperche S, Simon N. Efficacy of HCV core antigen detection during the pre-seroconvertion period. Transfusion 2000; 40: 1198-1202.

  64. Peterson J, Green G, Iida K, Caldwell B, Kerrison P, Bernich S, Aoyagi K, et al. Detection of hepatitis C core antigen in the antibody negative “window” phase of hepatitis C infection. Vox Sang 2000; 78: 80-85.

  65. Icardi G, Ansaldi F, Bruzzone BM, Durando P, Lee S, de Luigi C, Crovari P. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for core antigen. J Clin Microbiol 2001; 39: 3110-3114.

  66. Lee SR, Peterson J, Niven P, Bahl C, Page E, DeLeys R, Giordano-Schmidt D. Efficacy of hepatitis C virus core antigen enzyme-linked immunosorbent assay for the identification of “window-phase” blood donations. Vox Sang 2001; 80: 19-23.

  67. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, et al. Clinical utility of total hepatitis C virus (HCV) core antigen quantification, a new indirect marker of HCV replication. Hepatology 2002; 36: 211-218.

  68. Campello C, Poli A, Dal Molin G, Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. Infection 2002; 30: 7-12.

  69. Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Crocè LS, Mazzoran L, Masutti F, Cristianini G, Tiribelli C. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999; 44:874-80.




2020     |     www.medigraphic.com